Zhejiang Sundoc Pharmaceutical

Zhejiang Sundoc Pharmaceutical is a China-based biopharmaceutical company specializing in the development of high-end complex formulations, with a particular focus on long-acting injectables (LAI). The company utilizes proprietary technology platforms for microspheres, liposomes, and nanocrystals to create improved therapeutic versions of established drugs. Its clinical pipeline is primarily concentrated in the therapeutic areas of psychiatry, oncology, and endocrinology, featuring advanced candidates for schizophrenia, diabetes, and acromegaly. Notable programs include long-acting formulations of risperidone, aripiprazole, and exenatide, many of which are in late-stage clinical development or bioequivalence testing. Sundoc aims to address unmet medical needs by enhancing drug delivery, thereby improving patient adherence and clinical outcomes. The company is publicly traded on the National Equities Exchange and Quotations (NEEQ) in China.